Royalty Pharma (RPRX) Payables (2019 - 2026)
Royalty Pharma (RPRX) posted Payables of $25.5 million for Q1 2026, up 31.33% sequentially from $19.4 million in Q4 2025, and down 32.28% YoY from $37.6 million in Q1 2025.
Royalty Pharma (RPRX) Payables (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Payables for 8 years, with the latest figure at $25.5 million in Q1 2026.
- Quarterly Payables fell 32.28% year-over-year to $25.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.5 million (down 32.28% YoY) and the FY2025 annual result came in at $19.4 million, up 45.13% from the prior year.
- Payables advanced to $25.5 million in Q1 2026 per RPRX's latest filing, from $19.4 million in the prior quarter.
- Over five years, Payables peaked at $41.4 million in Q3 2025 and troughed at $5.8 million in Q2 2023.
- A 5-year average of $17.6 million and a median of $15.2 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2024: Payables plunged 52.29% in 2023, then surged 303.1% in 2024.
- Over 5 years, Payables stood at $7.9 million in 2022, then soared by 91.82% to $15.2 million in 2023, then declined by 11.84% to $13.4 million in 2024, then surged by 45.13% to $19.4 million in 2025, then surged by 31.33% to $25.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $25.5 million, $19.4 million, and $41.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.57 Mn |
| Mar 31, 2026 | 25.48 Mn |
| Dec 31, 2025 | 19.40 Mn |
| Sep 30, 2025 | 41.42 Mn |
| Jun 30, 2025 | 20.21 Mn |
| Mar 31, 2025 | 37.63 Mn |
| Dec 31, 2024 | 13.37 Mn |
| Sep 30, 2024 | 22.06 Mn |
| Jun 30, 2024 | 23.42 Mn |
| Mar 31, 2024 | 11.55 Mn |
| Dec 31, 2023 | 15.17 Mn |
| Sep 30, 2023 | 13.63 Mn |
| Jun 30, 2023 | 5.81 Mn |
| Mar 31, 2023 | 6.66 Mn |
| Dec 31, 2022 | 7.91 Mn |
| Sep 30, 2022 | 16.11 Mn |
| Jun 30, 2022 | 12.18 Mn |
| Mar 31, 2022 | 6.66 Mn |
| Dec 31, 2021 | 5.62 Mn |
| Sep 30, 2021 | 9.19 Mn |